New Targeted Therapies for HER2-Positive Metastatic Breast Cancer

Gain multidisciplinary perspectives on how to leverage novel and established HER2-targeted agents for optimal mangement of HER2-positive metastatic breast cancer with these downloadable slides from expert-led workshops and Webinars.

Share

Program Content

No activities added yet

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Puma Biotechnology, Inc.

Seagen